11:20 AM EDT, 10/21/2024 (MT Newswires) -- Trevi Therapeutics ( TRVI ) said Monday it has completed enrollment in its phase 2a trial to evaluate the efficacy, safety, tolerability and dosing of its experimental Haduvio treatment for refractory chronic cough.

The company expects to report topline data in Q1 of 2025.

Trevi shares were up nearly 5% in recent trading.

Price: 3.28, Change: +0.16, Percent Change: +4.97